Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
- 1 November 1995
- journal article
- Published by Elsevier in The Lancet
- Vol. 346 (8987) , 1399-1400
- https://doi.org/10.1016/s0140-6736(95)92408-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp)International Journal of Cancer, 1994
- Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+; human T cell clone by the autologous MHC class II+ melanomaInternational Immunology, 1993
- T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restrictionEuropean Journal of Immunology, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gin → Leu61)International Immunology, 1992
- Acute rejection in heart transplant patients is associated with the presence of committed donor-specific cytotoxic lymphocytes in the graft but not in the bloodClinical and Experimental Immunology, 1992
- Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.The Journal of Experimental Medicine, 1991
- A Cell Culture Model for T Lymphocyte Clonal AnergyScience, 1990